The initiation of the Phase 2a study for VTX3232 in Parkinson’s disease is promising, with initial data expected in the first half of 2025. However, the limited size of this study, involving only 10 ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

Ventyx stock shows all the characteristics of a highly underappreciated issue with surprisingly valuable assets that can be ...

In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

The transaction, which was expected to close on the same day as the announcement, grants Sanofi an exclusive right to first negotiation for VTX3232, Ventyx's drug candidate for Parkinson's disease and ...

This strategic move by Sanofi aligns with Ventyx's mission to address unmet medical needs in inflammatory diseases, particularly through its promising VTX3232 program. VTX3232, a novel oral therapy, ...

“Sanofi is a global leader in immunological and inflammatory diseases, and we believe this transaction is a recognition that VTX3232 could potentially offer a disease-modifying approach for the ...

Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx’s ...

NEWS ANALYSIS: Norwegian Prime Minister Jonas Gahr Støre was quick to congratulate Donald Trump on Wednesday, even before the final vote in the US presidential election was tallied. Støre stressed ...